Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology

TipRanksApr 9 18:17

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...

PR NewswireApr 9 04:30

Lori Hu Resigns, Darcy Mootz Joins Elevation Oncology Board

Elevation Oncology (ELEV) has shared an announcement.

TipRanksApr 6 04:34

Watching Elevation Oncology; Traders Circulate M&A Blog Comments Saying 'The Intensity Of M&A Interest Among ADC Developers As Well As A Transactional ELEV Management Team Have Made This Company Hard To Ignore'

Watching Elevation Oncology; Traders Circulate M&A Blog Comments Saying 'The Intensity Of M&A Interest Among ADC Developers As Well As A Transactional ELEV Management Team Have Made This Company Hard

BenzingaApr 3 22:10

Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan

Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution

MT NewswiresMar 28 05:30

HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs

HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs

BenzingaMar 26 20:54